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A B S T R A C T
Background: Anxiety and depression are common, debilitating and costly. These disorders are influenced by
multiple risk factors, from genes to psychological vulnerabilities and environmental stressors, but research is
hampered by a lack of sufficiently large comprehensive studies. We are recruiting 40,000 individuals with
lifetime depression or anxiety and broad assessment of risks to facilitate future research.
Methods: The Genetic Links to Anxiety and Depression (GLAD) Study (www.gladstudy.org.uk) recruits in-
dividuals with depression or anxiety into the NIHR Mental Health BioResource. Participants invited to join the
study (via media campaigns) provide demographic, environmental and genetic data, and consent for medical
record linkage and recontact.
Results: Online recruitment was effective; 42,531 participants consented and 27,776 completed the
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questionnaire by end of July 2019. Participants’ questionnaire data identified very high rates of recurrent de-
pression, severe anxiety, and comorbidity. Participants reported high rates of treatment receipt. The age profile
of the sample is biased toward young adults, with higher recruitment of females and the more educated,
especially at younger ages.
Discussion: This paper describes the study methodology and descriptive data for GLAD, which represents a large,
recontactable resource that will enable future research into risks, outcomes, and treatment for anxiety and
depression.
1. Introduction
Anxiety and depression are the most common psychiatric disorders
worldwide, with a lifetime prevalence of at least 30% (Bandelow &
Michaelis, 2015; Kessler et al., 2005). Both are highly comorbid with
each other and with other psychiatric disorders (Mineka, Watson, &
Clark, 1998), and account for 10% of all years lived with disability
(World Health Organisation, 2017). The World Health Organisation
now considers depression to be the number one disorder by burden of
disease (World Health Organisation, 2017). Many risk factors for de-
pression and anxiety are shared, including psychological (e.g. cognitive
biases (Michl, McLaughlin, Shepherd, & Nolen-Hoeksema, 2013;
Naragon-Gainey, 2010)), environmental (e.g. stressful life events
(Michl et al., 2013)), and genetic influences (which are ∼60–100%
shared (Purves et al., 2017; Waszczuk, Zavos, Gregory, & Eley, 2014)).
These findings on aetiology have been accompanied by an increasing
evidence base of effective treatments, especially psychological (talking)
therapies (Deacon & Abramowitz, 2004; Dobson, 1989; Hofmann &
Smits, 2008). Nevertheless, despite advancements in psychological
therapies as well as medication, clinicians are unable to predict which
treatment will work for whom. This means that the choice of first and
subsequent treatments currently progresses by trial and error at the cost
of prolonged disability, reduced hope of success/engagement, and in-
creased risk of adverse events (Perlis, 2016; Rush et al., 2006).
Decades of work estimate twin study heritability of both anxiety and
depression at ∼30–40% (Sullivan, Neale, & Kendler, 2000), rising to
∼60–70% for the recurrent forms of these disorders across several
years (Kendler, Neale, Kessler, Heath, & Eaves, 1993). Recent UK Bio-
bank analyses confirm that common genetic variants (single nucleotide
polymorphisms, or “SNPs”) account for a smaller but still significant
∼15–30% of variation (“SNP-heritability”) in lifetime anxiety (Purves
et al., 2017). Depression has a SNP-heritability of∼12–14% and shows
substantial genetic overlap with anxiety (Purves et al., 2017). Recent
genome-wide association studies (GWAS) have identified 102 genetic
variants for depression and closely related phenotypes (Howard et al.,
2019) and 5 genetic variants for anxiety (Purves et al., 2017), in-
dicating that we are now entering the era where it will be possible to
finally discover new biology for both disorders. In addition, these ge-
netic advances suggest that it may be time to include genetic risk factors
in research aimed at developing new treatments or predicting which
therapies will work best for each patient (Breen et al., 2016; Gaspar
et al., 2018; Keers et al., 2016; Lewis and Vassos, 2017).
Both GWAS and sequencing studies have shown that there are few,
if any, individual genetic variants with a large effect size. Instead, the
overall heritability is made of the effect of many (probably thousands)
genetic variants that individually have small effects. This type of ge-
netic architecture is now commonly referred to as being polygenic. As
such, almost all disorders affecting>0.5% of the population that show
moderate to high heritability are now referred to as polygenic dis-
orders. The use of genome-wide methodology has also confirmed that
psychiatric genetics has moved beyond its replication crisis, as its re-
sults have proven much more replicable than those of candidate gene
studies (Border et al., 2019).
Despite the broad range of established risk factors (Burcusa &
Iacono, 2007; Craske et al., 2017; Fliege, Lee, Grimm, & Klapp, 2009), it
is unclear how different types of influences combine to increase risk and
influence treatment response. In particular, clinical/psychological (e.g.
comorbidities), demographic (e.g. age), environmental (e.g. life
events), and genetic influences have been studied largely in-
dependently, despite their evident interplay (Kendler, Gardner, &
Prescott, 2002). As such, more multidisciplinary research is needed.
However, efforts to better understand the aetiology of these disorders
require large sample sizes and detailed information on symptom pre-
sentation. Many studies exist worldwide with either the scale of parti-
cipants or the thorough phenotyping needed, but few have both. In
response to this, the Genetic Links to Anxiety and Depression (GLAD)
Study was developed to recruit> 40,000 individuals into the newly
established National Institute for Health Research (NIHR) Mental
Health BioResource. Our sample size was based on the available
funding and our aim to be one of the largest single studies (as opposed
to previous meta-analyses) of individuals with a lifetime experience of
clinical depression and anxiety, providing sufficient power for dis-
covery analyses and for recall studies.
The NIHR Mental Health BioResource is an integral part of the
overall NIHR BioResource for Translational Research (https://
bioresource.nihr.ac.uk/), which has previously recruited approxi-
mately 100,000 individuals. However, a large majority of these vo-
lunteers were either healthy controls or have a physical health condi-
tion with no reported mental health disorder. This gap led to the
creation of the NIHR Mental Health Bioresource. GLAD is its first
Fig. 1. Steps to prepare for launch of the GLAD Study.
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project and has the specific goal of recruiting a large number of parti-
cipants with anxiety and depression to facilitate future recall and sec-
ondary data analysis studies. Recall studies would involve recontacting
participants to take part in further research, such as clinical trials aimed
at developing better therapies and interventions for anxiety and de-
pression. The GLAD Study will also directly explore both genetic and
environmental risk factors for depression and anxiety disorders, in-
cluding the potential of polygenic risk scores (Purcell et al., 2009)
created from analyses of related phenotypes to predict response to
treatment and prognosis. GLAD aims to facilitate studies which need to
combine genetic, phenotypic, and environmental exposure data by
creating a large, homogeneously phenotyped cohort of individuals with
depression or anxiety with all these types of data.
2. Methods
2.1. Pre-launch preparation
A focused and intense social media campaign was utilised to inform
the public about the GLAD Study. We hoped that individuals with an-
xiety and depression would be encouraged to join given the online
methodology, allowing them to respond to the questionnaires in a
convenient time and location. The timeline leading up to the media
launch is outlined in Fig. 1. Experts in the field, patients, and in-
dividuals with lived experience of depression or anxiety were consulted
at each stage of study development. The study team also consulted
regularly with collaborators from the Australian Genetics of Depression
Study who provided guidance and advice based on their experience of
successfully implementing a similar study design in Australia (Byrne
et al., 2019).
2.1.1. Website development, design, and user testing
The website was developed in collaboration with a local company
(Mindwave Ventures) in various stages. During the early stages of de-
velopment and the design phase, we conducted user testing on the
website by contacting individuals with lived experience through var-
ious routes. The first user testers were patient volunteers within the
Improving Access to Psychological Therapies (IAPT) service at South
London and Maudsley (SLaM) National Health Service (NHS)
Foundation Trust. The second group of volunteers were members of the
King's College London Service User Research Enterprise (SURE) and the
Feasibility and Acceptability Support Team for Researchers (FAST-R).
Third were volunteer individuals with lived experience who were ac-
tively involved with the charity Mind. Finally, staff from the charities
Mind, MQ Mental Health, and the Mental Health Foundation gave
feedback. All individuals provided input on the website content and
usability, appearance, and study information and all volunteers (but not
charity staff) were compensated £10 for their time. All feedback was
reviewed by the study team and the lead investigators and incorporated
into the final version of the website.
2.1.2. GLAD Study spokespeople
A wide range of charities, professional bodies, companies, influen-
cers (defined as individuals with a large number of followers on social
media), and individuals with lived experience were identified based on
previous advocacy, involvement, or openness of mental health and
treatment. These individuals and organisations were approached by the
public relations (PR) company (Four Health Communications), the
study team, and/or the co-investigators to introduce the study and in-
vite them to collaborate.
We received support from many UK charities including Mind, MQ,
Mental Health Foundation, Anxiety UK, OCD Action, Bipolar UK,
HERO, No Panic, the Charlie Waller Memorial Trust, BDD Foundation,
Maternal OCD, Rethink Mental Illness, SANE, MHFA England,
Universities UK, and UK Youth. We also received significant support
from two UK professional bodies for psychologists and psychiatrists: the
British Psychological Society and the Royal College of Psychiatrists.
Finally, three organisations (Royal Mail, Priory Group, and Barnardo's)
agreed to circulate study information internally to their employees, and
Priory Group additionally shared study information on social media.
Many of the charities, professional bodies, and influencers provided
a quote about the GLAD Study to be shared with news outlets and on
social media. Other forms of support from charities or professional
bodies included circulating study information in member newsletters or
magazines, publishing study information on their websites, and sharing
the study on social media (http://wke.lt/w/s/Ymfhz). Influencers
helped to promote the study on their social media channels or blogs.
Individuals with lived experience allowed the GLAD Study team to
share their stories on social media and news outlets. Of utmost im-
portance, these individuals were available for interviews with broadcast
and newspaper agencies and gave a personal voice to the campaign.
Spokespeople who became actively involved in the publicity and cir-
culation of the GLAD Study in the media and/or online were vital to the
success of the campaign.
2.1.3. Standard operating procedures and templates
We created a variety of standard operating procedures (SOPs) and
response templates to prepare for the logistical and administrative as-
pects of study launch and management. These included SOPs for saliva
sample kit preparation and posting, website management, data pro-
tection, and participant contact. We established guides and SOPs for
both email and social media responses to participant questions, con-
cerns, and expressions of distress. These guidelines were reviewed by
clinicians and by the Mental Health Foundation to ensure responses
were appropriate, straightforward, and clear.
2.1.4. Social media content and visuals
Social media content and visuals were designed with the aid of the
PR company (which had experience of working on NHS projects), an
independent videographer, and an animation company. These included
a range of infographics and short videos, each designed to be in-
formative and provide basic details for the public about the aims of
GLAD and how to join the project. The campaign was targeted to a
younger demographic (age 16–30) to enable more prolonged collection
of longitudinal data and reflect the young age of onset of depression
and anxiety disorders (Bandelow & Michaelis, 2015; Christie et al.,
1988; Kessler et al., 2005).
The infographics (Fig. 2) emphasised the simplicity and ease of
taking part. The consent animation (https://youtu.be.com/
SAE0yVNvWaA) outlined key elements of the consent process to pro-
vide a simple and clear way to learn about the study, consistent with
guidance from the Health Research Authority regarding multimedia use
as a patient-friendly method of delivering vital consent information
(Health Research Authority, 2017). The consent animation was also
included with the website version of the information sheet. The second
Fig. 2. GLAD Study infographic shared on Twitter
Example of the infographic shared on Twitter to promote the GLAD study and
explain the key steps involved in signing up.
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video was a short film (https://youtu.be/wzgvS8gU2Ss) which outlined
the study sign-up steps in a real-life, relatable way. Finally, the ani-
mation (https://youtu.be.com/HUI5eFXevvk) was an engaging ‘call to
action’ to join the community of volunteers participating in the GLAD
Study.
We created a six-week social media schedule for planned posts
across Facebook, Instagram, and Twitter platforms which included both
organic and promoted content. Most of the posts were accompanied by
a video, infographic, or other imagery developed by the study team.
2.1.5. Outreach to news outlets
The PR company circulated the press release and study information
to news and broadcast agencies across England, and later across the rest
of the UK. Interested parties organised interviews with the study in-
vestigators and/or influencers, charity or professional body re-
presentatives, and individuals with lived experience. The press releases
and broadcasts were embargoed until the launch date to prevent pre-
emptive publicity and provide uniform, widespread coverage across
different media.
2.2. Recruitment
2.2.1. Media campaign: study launch
The PR company helped us to organise a widespread national media
campaign which included traditional media (TV, radio, newspaper) and
social media (Twitter, Facebook, Instagram) outreach during the study
launch. Examples from the campaign can be viewed at this link: http://
wke.lt/w/s/Ymfhz. In the first 24 h, 8004 participants had registered to
the website, demonstrating the effectiveness of this strategy. The pre-
pared social media schedule helped to maintain our recruitment num-
bers over the six-week period. Between 300–1500 participants signed
up to the study daily, with numbers fluctuating based on campaign
expenditure and social media support from influencers and organisa-
tions.
Five months after the initial launch, the GLAD Study opened in
Northern Ireland, Scotland, and Wales, in collaboration with re-
searchers at Ulster University,2 the University of Edinburgh, and Cardiff
University. The press offices of the respective universities organised
media outreach to local and national news outlets, and the PR company
assisted in targeted social media advertisements for the various coun-
tries.
2.2.2. Clinical recruitment
In the 10 months following the launch, many NHS organisations in
England contacted us interested in supporting the GLAD Study. As of
July 2019, these included 12 Clinical Research Networks (CRN), 7 fa-
mily doctor/general practitioner (GP) practices, 96 Trusts, 1 Clinical
Commissioning Group (CCG), and 2 GP Federations. Sites were classi-
fied in 2 different categories with varying levels of involvement: 1)
advertising sites which displayed study posters and leaflets in clinics
and waiting areas, and 2) recruiting sites which conducted mail-outs,
approached patients in the clinic or over the phone, and assisted pa-
tients through the study sign-up process.
2.2.3. Sign-up process
The sign-up process for enrolment in GLAD is given in Fig. 3. Per-
sonal information and phenotypic data are collected entirely online
through the GLAD Study website (www.gladstudy.org.uk). Participants
register on the website with their name, email address, phone number,
date of birth, sex, and gender. They are then able to read the in-
formation sheet and provide consent. As part of the consenting process
participants agree to long-term storage of their sample, requests to
complete follow-up questionnaires, anonymised data sharing, recontact
for future research studies based on their phenotype/genotype in-
formation, and access to their full medical and health related records.
Following consent, participants complete the sign-up questionnaire to
assess their eligibility. Eligibility criteria are restricted to participants
that meet DSM-5 criteria for MDD or any anxiety disorder, based on
responses to screening measures in our online sign-up questionnaire.
More information about the measures in the sign-up questionnaire are
included below. Eligible participants are then sent an Isohelix saliva
DNA sample kit. Saliva samples are sent via Freepost to the NIHR Na-
tional Biosample Centre in Milton Keynes for processing and storage.
Once participants have returned their saliva sample, they become full
members of the GLAD Study (and of the NIHR BioResource) and are
eligible to take part in future studies.
Email reminders are sent to participants who do not complete their
sign-up steps. Up to four automated reminder emails are sent through
the website up to six months post starting sign-up. Once online sign-up
steps are completed, a maximum of four reminder emails are sent to
participants regarding the saliva samples up to six months from the date
the kit was sent. We conduct additional phone call or text message
reminders to participants who have not returned their saliva kits within
three months of signing-up.
Clinical data will be linked to genotype and phenotype data to
provide additional information about participants’ medical history, di-
agnoses, and treatments relevant to current and future research pro-
jects. Eligibility for collaborating studies can then be assessed utilising
all phenotypic, genetic, and clinical data. Members may then be con-
tacted up to four times per year to take part in future studies, either
through the website or by the GLAD Study or NIHR BioResource teams,
with access granted via established NIHR BioResource access protocols
(see below for further detail). As part of the community of members,
participants will also have access to useful information and links on the
“Useful Links” page of the study website. Members will also be invited
to take part in follow-up questionnaires to provide longitudinal data on
their symptoms.
2.3. Measures
2.3.1. Sign-up questionnaire
The sign-up questionnaire was designed to assess core demographic,
mental and physical health, comorbidities, and personal information as
well as detailed psychological and behavioural phenotyping relevant to
anxiety and depression (for full measure names see Table 1). We in-
cluded lifetime measures of major depressive disorder (MDD), atypical
depression, and generalised anxiety disorder (GAD), adapted from CIDI-
SF (Patten, Brandon-Christie, Devji, & Sedmak, 2000) and ICD-11
checklists (Kogan et al., 2016), supplemented with items enabling
lifetime assessment of DSM-5 specific phobia, social phobia, panic
disorder and agoraphobia. These items were adapted from the Aus-
tralian Genetics of Depression Study questionnaire (Byrne et al., 2019).
We also assessed current depressive symptoms (PHQ-9 (Kroenke,
Spitzer, & Williams, 2001)), and those with a score of five or above on
the PHQ 9 (indicating a current episode of depression) were asked
additional questions related to current treatment-resistant depression
(MSM-SR (Fekadu, Donocik, & Cleare, 2018)). Other measures of cur-
rent psychopathology included possible mania/hypomania (MDQ
(Hirschfeld, 2002)), current general anxiety symptoms (GAD-7 (Spitzer,
KroenkeWilliams, & Löwe, 2006)), post-traumatic stress disorder
symptoms (PCL-6 (Lang et al., 2012)), alcohol use (AUDIT-C (Saunders,
Aasland, Babor, de La Fuente, & Grant, 1993)), psychotic symptoms
(adapted CIDI (McGrath et al., 2015)), personality disorder symptoms
(SAS-PD (Olajide et al., 2018)), and work and social adjustment (WSAS
(Marks, 1986)). Additional measures were included to assess subjective
well-being (WHOQOL Group, 1994), recent adverse life events, five
childhood trauma items (Glaesmer et al., 2013) representing the five
2 Professor Chérie Armour, the Principal Investigator (PI) in Northern Ireland
(NI) moved institution during the course of the study from Ulster University to
Queens University Belfast, remaining as the NI PI.
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subscales of the full Childhood Trauma Questionnaire (Pennebaker &
Susman, 2013), domestic violence (Davis et al., 2018), and catastrophic
trauma (Davis et al., 2018).
To facilitate future meta-analyses with other cohorts, measures were
selected when possible to align with the UK Biobank Mental Health
Questionnaire (MHQ) (Davis et al., 2018). Participants were also asked
to report if they have taken part in the UK Biobank. Some aspects of the
UK Biobank MHQ were not selected for the sign-up questionnaire in
order to make space for additional measures more relevant here. Fur-
thermore, detailed questions on self-harm and suicide were not asked
during sign-up due to concerns from the study team and the SLaM
Research and Development (R&D) department of insufficient clinical
support in the case of reported adverse events, although the single
suicidal ideation item in the PHQ-9 was retained as this measure is
validated and widely used.
2.3.2. Optional questionnaires
Once participants completed the sign-up questionnaire, they were
invited to take part in additional, optional questionnaires (SM 1).
Optional questionnaires to assess a wider number of psychiatric phe-
notypes and symptoms included measures of fear (Fear Survey Schedule
(Wolpe & Lang, 1964)), drug use (DUDIT (Berman, Bergman,
Palmstierna, & Schlyter, 2003)), obsessive-compulsive disorder (OCI-R
(Foa et al., 2002)), post-traumatic stress disorder (PCL-5 (Weathers
et al., 2013)), trauma (Kopenen, personal communication), postnatal
depression (EPDS (Cox, Holden, & Sagovsky, 1987)), body dysmorphic
disorder (DCQ (Mancuso, Knoesen, & Castle, 2010)), eating disorders
(Allison, Stunkard, & Thier, 2004; Herman et al., 2016; Hildebrandt,
Jim Langenbucher, & Schlundt, 2004; Thornton et al., 2018), and vomit
phobia (SPOVI (Veale, Ellison, Mark, &
BoschenCostaWhelanMuccioHenry, 2013)).
Other optional projects relate to lifestyle and personal history,
asking detailed questions on participants’ experience of healthcare, life
events (Weathers et al., 2013), work and sleep, general health and
lifestyle, gambling, and headaches and migraines (Byrne et al., 2019).
Optional questionnaires were made available to all participants, except
those on vomit phobia and postnatal depression which were only of-
fered to participants based on responses to screening questions in the
sign-up questionnaire. Additional follow-up questionnaires will be sent
to participants annually to provide longitudinal data on symptoms and
outcomes.
2.4. Genotyping
All GLAD samples will be genotyped as part of core NIHR
BioResource funding. For genotyping we are using the UK Biobank v2
Axiom array, consisting of> 850,000 genetic variants (Bycroft et al.,
2018), designed to give optimal information about other correlated
genetic variants. This careful design means that imputation of the data
with large whole genome sequencing reference datasets will yield> 10
million common genetic variants per individual. We use Affymetrix
software and the UK Biobank pipeline software to assign genotypes and
perform standard quality control measures in PLINK (Chang et al.,
2015) or equivalent software packages and R (Team, 2015). Analyses
Fig. 3. Stages of participant sign-up and involvement in the GLAD Study.
Table 1
GLAD Study sign-up questionnaire measures.
Assessment/Topic Purpose Source
Lifetime depression Lifetime assessment of major depressive disorder Adapted Composite International Diagnostic Interview – Short Form (CIDI-SF)
Lifetime atypical depression Lifetime assessment of atypical depression Adapted DSM-5/ICD-11 checklists
Lifetime anxiety Lifetime assessment of generalised anxiety disorder Adapted Composite International Diagnostic Interview – Short Form (CIDI-SF)
Lifetime specific phobia Lifetime assessment of specific phobia Adapted DSM-5/ICD-11 checklists
Lifetime social phobia Lifetime assessment of social phobia Adapted DSM-5/ICD-11 checklists
Lifetime panic disorder Lifetime assessment of panic disorder Adapted DSM-5/ICD-11 checklists
Lifetime agoraphobia Lifetime assessment of agoraphobia Adapted DSM-5/ICD-11 checklists
Current depressive symptoms Assess severity and presence/absence of current
depression.
Patient Health Questionnaire 9-items (PHQ-9)
Treatment-resistant depression Assess treatments during most recent or current
depressive episode to screen for treatment-resistant
Maudsley Staging Model of Treatment Resistance, Modified Self-Report (MSM-SR)
Possible mania/hypomania Screen participants for possible episodes of
hypomania or mania
The Mood Disorder Questionnaire (MDQ)
Current general anxiety symptoms Assess the severity and presence/absence of current
anxiety
Generalised Anxiety Disorder 7-item scale (GAD-7)
Current post-traumatic stress
disorder symptoms
Screen for presence and severity of PTSD symptoms. Post-traumatic stress disorder checklist, civilian version 6-items (PCL-6)
Alcohol use Screen for alcohol dependence in the past year Alcohol Use Disorders Identification Test (AUDIT)
Psychotic symptoms Assess lifetime psychotic experiences Adapted CIDI
Personality disorders Assess the severity of personality disorders. Standardized Assessment of Severity of Personality Disorder 9-items (SASPD)
Work and social adjustment Assess functional impairment due to psychopathology Work and Social Adjustment Scale (WSAS)
Subjective wellbeing Assesses subjective well-being, specifically positive
emotion and meaning
Two hedonic (‘positive emotion’) questions and a eudaimonic (‘meaning’) question
from WHO-Quality of Life (WHOQOL)
Adversities in childhood Identify presence/absence of childhood abuse and
neglect
Childhood Trauma Screener short version (CTS-5)
Adult domestic abuse and
catastrophic trauma
Identify victims of adult domestic abuse. A 5-item domestic abuse screen developed for the UK Biobank Mental Health
Questionnaire, adapted from the national crime survey and CTS-5, and 5 items on
catastrophic trauma
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will be conducted in PLINK in the first instance.
Ethical approval
The GLAD Study was approved by the London - Fulham Research
Ethics Committee on 21st August 2018 (REC reference: 18/LO/1218)
following a full review by the committee. The NIHR BioResource has
been approved as a Research Tissue Bank by the East of England -
Cambridge Central Committee (REC reference: 17/EE/0025). Prior to
submission for ethical approval, this research was reviewed by a team
with experience of mental health problems and their carers who have
been specially trained to advise on research proposals and doc-
umentation through the Feasibility and Acceptability Support Team for
Researchers (FAST-R): a free, confidential service in England provided
by the NIHR Maudsley Biomedical Research Centre via King's College
London and South London and Maudsley NHS Foundation Trust.
2.5. Analysis
2.5.1. Genetics and combined predictors of anxiety and depression
The GLAD data can be used alongside UK Biobank for meta-ana-
lyses, with UK Biobank participants and/or other NIHR Bioresource
participants as healthy controls, to maximise statistical power. One of
our primary genomic aims is to utilise polygenic scores created from
very large genome-wide analyses of related traits (e.g. anxiety) as po-
tential predictors of depression, anxiety, and treatment response in our
sample. There are a number of well-powered polygenic scores now
available in the field not only for psychiatric traits but also intelligence
and its proxies (Selzam et al., 2017) and other relevant predictors. We
aim to combine these polygenic scores with significant clinical pre-
dictors to produce a combined clinical/genetic risk index.
We envision the GLAD sample to also be incorporated either in large
genome-wide association studies, contributing to meta-analyses, or in
clinical trials, for example researching genetic, epidemiological or so-
cial risk factors of anxiety and depression.
2.6. Future research and collaborations
Researchers wishing to access GLAD Study participants or data are
invited to submit a data and sample access request to the NIHR
BioResource to request a collaboration, following the procedures out-
lined in the access request protocol (SM 2). Applications will be re-
viewed by the NIHR Steering Committee to assess the study aims and to
check ethical approvals and protocols. Collaborations can range from
sharing of anonymised data or samples to recontact of participants for
additional studies, including experimental medicine studies and clinical
trials. Eligibility for future research can be targeted to specific geno-
types and/or phenotypes of interest.
3. Results
3.1. Sample descriptors
Recruitment of the GLAD Study is ongoing. All results that follow
are from participants recruited before 25 July 2019. As of this date,
42,531 participants had consented to the GLAD Study, with approxi-
mately 35% drop-off rate at each stage of the sign-up process. This
resulted in 27,991 (65.8%) having completed the questionnaire, with
27,776 (99.2%) screened as eligible and sent a saliva kit. Of those
participants which were sent a kit, 18,663 (67.2%) have returned a
saliva sample thus far.
In the current sample, the mean age is 38.1 with most participants
being female, white, and in paid employment or self-employed
(Table 2). The GLAD sample is younger and more female (Fig. 4) and
has a higher proportion of individuals with a university degree (Fig. 5)
than the general UK population. For example, 13.1% of our sample is
female aged 25–29 compared to only 4.2% of the UK population. This
difference is seen across all age groups under 60. Similarly, in the age-
range 25–34 years, 68.9% of the sample have a university degree,
whereas in England and Wales this is only 40.4%. In total, 54.8% of the
GLAD sample have a university degree compared to 27.2% of the
English and Welsh population. Matching educational attainment data
was not readily available for Northern Ireland and Scotland.
A high proportion of GLAD participants report the occurrence of at
least one form of trauma or abuse throughout their lives (see Table 3).
Child abuse was most commonly reported, with emotional abuse by
parents or family being endorsed by 42.1% of the sample (in compar-
ison to the estimated 9% of adults in England and Wales who experi-
enced emotional abuse as a child (Office for National Statistics, 2016)).
Other forms of life stress are also frequently endorsed with 62.8% of the
Table 2
Descriptors of GLAD sample, July 2019.
Percenta
Sex
Male 20.3%
Female 79.7%
Gender
Transgender 1.5%
Sexuality
Heterosexual 73.4%
Homosexual 6.5%
Bisexual 15.5%
Asexual 1.3%
Self-define 3.1%
Ethnicity
White 94.8%
Mixed 2.5%
Asian or Asian British 1.2%
Black or Black British 0.5%
Arab 0.1%
Other 0.9%
Education (highest level achieved)
College or university degree 54.8%
A levels/AS levels or equivalent 22.7%
O levels/GCSEs or equivalent 14.8%
CSEs or equivalent 1.8%
Employment
Employed 59.5%
Retired 5.7%
Unable to work because of sickness or disability 11.8%
Unemployed, looking after home/family, or doing voluntary work 8.9%
Full or part-time student 13.0%
Relationship status
Single 27.8%
Relationship 32.2%
Married/civil partnership 30.3%
Divorced/separated 7.6%
Widowed 1.1%
Smoking status
Current 17.5%
Former 31.9%
Never 50.6%
Handedness
Right handed 87.2%
Left handed 11.1%
Ambidextrous 1.7%
Received treatmentb
Any treatment 96.1%
Psychological (talking) therapies 81.6%
Medication 89.7%
a Where totals do not sum to 100%, the remaining % was due to incomplete
data from those who declined to answer.
b Treatment percentages were only calculated for participants who screened
positively for MDD or GAD. Participants were asked to select all that applied in
response to the question “Did you ever try or are currently trying the following
for these problems?” Participants are considered to have received treatment if
they indicated they tried medication prescribed for at least two weeks or tried
psychotherapy or other talking therapy more than once.
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sample reporting at least one traumatic experience in their lives. Of
note, few participants reported periods of inability to pay rent, re-
flecting low rates of poverty in the sample.
3.2. Psychopathology
As shown in Fig. 6, the majority of participants reached diagnostic
criteria for major depressive disorder, followed by panic disorder and
generalised anxiety disorder. The majority of participants with de-
pression reported recurrent episodes across the lifespan. A figure de-
monstrating self-reported clinician-provided diagnoses of mental health
disorders (as opposed to questionnaire-assessed) in the GLAD sample
can be found in supplementary materials (SM 3). Of note, self-reported
clinician-provided diagnoses of GAD (77.2%) are twice as high as cases
assessed by the questionnaire. The sample also has high rates of
comorbidity, with 67.0% of screened MDD cases also screening posi-
tively for at least one of the anxiety disorders (GAD, specific phobia,
social phobia, panic disorder, or agoraphobia), and 95.1% of screened
GAD cases also screening positively for MDD.
Retrospective reports of age of onset indicate a young average onset
for the lifetime measures of MDD, GAD, specific phobia, social phobia,
panic disorder, and agoraphobia (Table 4). Average age of onset across
the anxiety disorders was∼15. Age of onset for GAD was added to the
questionnaire in May 2019, therefore the descriptives below are based
on responses from a subset of participants recruited after that date.
Measures of current symptoms of psychopathology included in the
questionnaire demonstrate high rates of current clinical presentation of
MDD and GAD, with high levels of functional impairment (Table 5).
Fig. 4. Distribution of sex and age in the GLAD
sample compared to the UK population
Comparison of age and sex characteristics be-
tween the GLAD sample and the general popu-
lation of the UK as measured in the 2011 census
(Office for National Statistics, National Records
of Scotland, and Northern Ireland Statistics and
Research Agency, 2016). Proportions of males in
each age group are displayed on the left side of
the graph, with female proportions on the right.
Percentages represent the proportion out of the
respective sample as a whole (GLAD or UK). For
example, 2.8% of the UK population is male
aged 16–19, compared to 0.7% of the GLAD
population. GLAD participants are represented
in light (male) and dark (female) shades of blue,
while the UK population is represented in light
(male) and dark (female) shades of green.
Fig. 5. Proportion of individuals with university
degrees within age groups in the GLAD sample
compared to the English and Welsh population
Comparison of education level by age group
between the GLAD sample and the general po-
pulation of England and Wales as measured in
the 2011 census (Office for National Statistics,
National Records of Scotland, and Northern
Ireland Statistics and Research Agency, 2016).
Data for Northern Ireland and Scotland was not
readily available. Proportions of individuals
without university degrees within each age
group are displayed on the left side of the graph,
with proportions of individuals with university
degrees on the right. Percentages represent the
proportion within each age group with or
without a university degree. For example, 14%
of the English population between the ages of
16–24 have a university degree compared to
36% of the GLAD population. GLAD participants
are represented in dark (no university degree)
and light (university degree) shades of blue,
while the English/Welsh population is re-
presented in dark (no university degree) and
light (university degree) shades of green.
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3.3. Media campaign
In order to assess the success of the media campaign, participants
were asked to report how they found out about the GLAD Study at the
end of the sign-up questionnaire. Results of the campaign were assessed
3 months after the initial launch in England. Participants who com-
pleted the questionnaire reported that the three most common ways of
hearing about the study were through Facebook, print newspaper, and
Twitter (SM 4).
The effectiveness of each recruitment strategy varied by age (see
Fig. 7). Of participants aged 16–29, the majority learned about the
study through social media (Facebook, Twitter, Instagram, search en-
gine), with only 12% receiving study information through traditional
media (TV, radio, print newspaper, online tabloid). Participants aged
30–49 also primarily learned about the study through social media, but
22% within that range learned about the study through traditional
media. Social media was less effective in reaching individuals aged
50+, with traditional media being the primary means of recruitment
above that age.
4. Discussion
The GLAD Study represents a large and comprehensive study of
anxiety and depression and a valuable resource for future research. By
achieving our goal of recruiting 40,000 participants with a lifetime
occurrence of one of these disorders into the NIHR Mental Health
BioResource, the study will collect detailed, homogenous phenotype
and genotype data, thereby increasing power for genetic analyses.
Importantly, the recontactable nature of GLAD means that researchers
will be able to conduct new studies integrating psychological and ge-
netic data.
Why integrate genetic data? GLAD provides researchers with a way
of investigating polygenic and environmental effects in studies with
participants. As such, the study is not merely a way to increase GWAS
sample size, but also a way to increase the potential utility of genomics
within psychological studies of all kinds. Previous efforts in depression
and anxiety genetics have been hampered by the unreliable metho-
dology of candidate gene studies (Border et al., 2019). However, Border
also concluded that modern and successful genome-wide studies of
depression, rigorously testing millions of genetic variants in large
samples (e.g. CONVERGE consortium, 2015; Wray et al., 2018), provide
reliable evidence. The implications that these highly complex, but
highly replicable, polygenic effects have for the field need to be in-
vestigated (Hyman, 2018). GLAD exists to enable recruitment of par-
ticipants into studies not only on the basis of their self-reported in-
formation and/or clinical records, but also on the basis of the
increasingly well powered method of polygenic risk scoring. This ap-
proach combines risk alleles across the genome into a single quantita-
tive measure for any one individual (Belsky and Harden, 2019). For
instance, a clinical trial could be undertaken with selection of partici-
pants based on past medical history and/or polygenic scores for a re-
levant trait.
External researchers will be able to apply for access to anonymised
data and will have the opportunity to recontact participants for addi-
tional data collection. This offers the prospect of a wide range of future
recall studies, including clinical trials, observational studies, neuroi-
maging, and experimental medicine. Recruitment for recall studies
could also be targeted to participants with phenotypes or genotypes of
interest by utilising GLAD data to screen for specific eligibility criteria,
thereby simplifying and expediting the recruitment process for future
studies. Furthermore, measures were in part selected to match other
cohorts and facilitate meta-analysis with samples such as the UK
Biobank, Generation Scotland, and the Australian Genetics of
Depression Study, although demographic differences between the
samples would need to be taken into account (e.g. age differences be-
tween GLAD and UK Biobank participants). We propose that the GLAD
data could be useful for stratifying cases into distinct phenotypes of
depression and anxiety to reduce heterogeneity, a strategy which has
been shown to increase the power of genetic analyses to detect sig-
nificant effects (CONVERGE consortium, 2015; Power et al., 2017;
Verduijn et al., 2017).
Initial descriptive analyses reveal that the current GLAD sample
does not reflect the demographics of the general population of the UK.
The limited ethnic diversity within the sample is not representative,
with 95% of participants being white compared to 87% of the popu-
lation (Office for National Statistics, National Records of Scotland, and
Northern Ireland Statistics and Research Agency, 2016). Similarly, al-
though common mental disorders are more than twice as common in
young women compared to young men, and 1.5 times more common in
women overall (NHS Digital, 2016), the GLAD sample remains dis-
proportionately female. Finally, roughly double the proportion of the
study sample report having a university degree compared to the English
and Welsh population.
The GLAD sample as a whole also shows severe psychopathology.
Our lifetime questionnaire diagnostic algorithm indicated that the
majority of the sample have recurrent depression, and 20.9% report
possible mania/hypomania. Over half the sample screen positively for a
lifetime anxiety disorder, with panic disorder being the most common.
Participants also show substantial comorbidity, in particular for GAD
cases reporting a concurrent diagnosis of MDD. Our results show sig-
nificantly higher comorbidity rates for GAD cases compared to a pre-
vious epidemiological study whereby 62.4% of GAD cases had a
Table 3
Proportion of the GLAD sample reporting previous child abuse/neglect, do-
mestic abuse, or traumatic life events.
Proportion of sample
Child abuse/neglecta
Any abuse or neglect 55.4%
Emotional abuse 42.1%
Physical abuse 20.2%
Sexual abuse 20.1%
Emotional neglect 14.8%
Physical neglect 4.2%
Domestic abuseb
Any abuse 30.6%
Emotional abuse 37.0%
Physical abuse 19.0%
Sexual abuse 22.6%
Stressful life event
Any stressful/traumatic life eventd 62.8%
Sexual assaultc 44.7%
Attacked, mobbed, or robbedc 26.7%
Life-threatening accidentc 13.3%
Witnessed sudden/violent deathc 15.4%
Life-threatening illnessc 8.8%
War zonec 2.1%
Inability to pay rent 1.6%
a Childhood abuse was assessed by the Childhood Trauma Survey (CTS)
(Glaesmer et al., 2013) which includes 5 items on a Likert scale, each relating to
the frequency of a distinct type of abuse (emotional, physical, sexual) or neglect
(emotional, physical). Percentages reflect the proportion of the sample scoring
above the defined cut-off point for clinical utility on each item out of the total.
b Domestic abuse and inability to pay rent was assessed by a separate adult
trauma scale without pre-defined cut-offs, therefore cut-off points were devised
by the study team based on the CTS scoring. a,b,dAny abuse or stressful/trau-
matic life event was defined as individuals who scored above the cut-off on at
least one item on the respective scale.
c The remaining stressful life events were assessed by combining the sum
total of participants indicating “Yes, in the past 12 months” or “Yes, but not in
the past 12 months” for each item.
d Any stressful/traumatic life event was defined as individuals who scored
above the cut-off point for inability to pay rent or indicated they had experi-
enced one of the stressful/traumatic life events either in the past 12 months or
in their lifetime.
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lifetime occurrence of MDD (Judd et al., 1998). However, this is likely
further indication of the sample's severity, reflecting previous reports of
higher rates of comorbid anxiety in patients with recurrent lifetime
depression (Boland, Keller, Gotlib, & Hammen, 2002; Moffitt et al.,
2007). In terms of current symptoms, GLAD participants report mod-
erate symptoms of depression, mild to moderate symptoms of anxiety,
and significant functional impairment, indicating poor work and social
adjustment. Finally, it was interesting to note that 55.0% of participants
screened positive for mild-moderate personality disorder.
Severity levels are also demonstrated by the 96.1% of GLAD parti-
cipants who report receiving treatment for depression or anxiety, al-
though the study is open to individuals regardless of treatment receipt.
In Western countries, it is estimated that between one-thirds and one-
half of patients with depression or anxiety disorders do not receive a
diagnosis and/or treatment (Kessler, Bennewith, Lewis, & Sharp, 2002),
a group not represented in our sample. However, even in those patients
receiving treatment, recent research suggests that only 20% get mini-
mally adequate treatment (Thornicroft et al., 2017), meaning that
follow-up research on treatment efficacy in the GLAD sample would be
highly valuable.
An unanticipated benefit of the campaign was the interest it gen-
erated from UK NHS sites around the country. Over 100 NHS sites,
including Trusts and GP practices, contacted the study team with
interest in supporting recruitment, and many had learned about the
study from the media campaign. The study was also adopted onto the
NIHR Clinical Research Network (CRN) Portfolio which provides sup-
port and funding for NHS organisations that are involved in research.
The combined approach of both general and clinical recruitment
reaches a wider demographic of participants than either strategy alone.
Patients recruited through clinics can also be assisted in signing up by a
local clinician or research team to provide support throughout the
process if needed.
In addition to collecting a large amount of data, the GLAD study
represents a template for future online studies. The media campaign
proved highly effective in recruiting a large number of participants in a
short amount of time and demonstrates the success of such a broad
outreach approach. Caution must be taken when interpreting the suc-
cess of the different media campaign strategies, given the prolonged use
of social media promotions in comparison to traditional media outlets;
nonetheless social media was the most effective strategy for recruiting
individuals under 50. Recruiting younger participants not only reflects
the young average age of onset of anxiety and depression, approxi-
mately 11 (Bandelow & Michaelis, 2015) and 24 (Christie et al., 1988;
Kessler et al., 2003) respectively, but also helps to facilitate long-term
follow up and recontact.
4.1. Limitations
As previously mentioned, the current demographics of study parti-
cipants who completed the questionnaire are not representative of the
population of the UK. This suggests a selection bias comparable to what
has been observed in similar studies such as the UK BioBank (Fry et al.,
2017; Adams et al., 2019). Results from analyses of the current GLAD
sample therefore may not be generalisable to the whole population.
Smaller studies could overcome these biases by selectively over-sam-
pling males and individuals at the lower end of educational attainment
to be more representative of the population.
However, efforts are being taken to recruit a wider demographic of
Fig. 6. Lifetime prevalence of probable psychiatric disorders in the GLAD sample.
Percentages refer to the proportion of participants who meet cut-off criteria on lifetime measures for the specified disorder as defined by the DSM-5 (American
Psychiatric Association, 2013) out of the total. Possible mania was assessed by the Mood Disorder Questionnaire (MDQ) (Hirschfeld, 2002).
Table 4
Age of onset in GLAD sample for major depressive disorder, specific phobias,
social phobia, panic disorder, and agoraphobia.
Median Mean SD
Major depressive disorder 16 18.61 8.98
Generalised anxiety disorder 16 19.37 11.87
Specific phobia 10 11.32 8.40
Social phobia 12 13.79 8.64
Panic disorder 16 18.80 10.21
Agoraphobia 15 16.90 10.10
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participants into the study. Specifically, we will develop a targeted
social media campaign to reach young men and collaborate with young
male influencers to appeal to that audience. We will additionally pre-
pare a future media campaign that focuses on depression and anxiety
separately, with wording specific to each disorder, to attempt to reduce
the high comorbidity rates in the sample. Furthermore, we are colla-
borating with local branches of the charity Mind. These are typically
placed within the community and provide a range of mental health
support services. Branches will be displaying posters and leaflets on
site, posting on social media, and answering questions or providing
assistance to potential participants interested in signing up.
Recruitment through NHS services and the availability of local research
teams within those sites will also help reach the general population and
recruit individuals with a wider range of educational attainment.
Of particular importance, we are working with Black, Asian, and
minority ethnic charities and influencers to conduct additional user
testing to understand the barriers to participating for non-white in-
dividuals and increase outreach to diverse communities. Previous ge-
netic studies have involved primarily individuals of white European
ancestry (Haga, 2010), and findings from these studies may not apply to
individuals of non-white descent. By actively recruiting a diverse
sample, our objective is to additionally facilitate research on typically
underrepresented groups.
Another challenge of the study design is the drop-out rates following
recruitment. At each stage of the sign-up process, a substantial number
of participants did not complete the next step despite multiple re-
minders. Unfortunately, we are unable to assess the demographics of
participants who do not complete the sign-up questionnaire, but it is
possible that the drop-outs are non-random and represent a certain
phenotype, such as individuals with more severe symptoms or lower
health literacy.
5. Conclusion
The GLAD Study offers a recontactable resource of participants with
a lifetime occurrence of depression and anxiety disorders to facilitate
future health research. The online study design and media recruitment
strategy were effective in recruiting a large number of individuals with
these disorders into the NIHR Mental Health BioResource. Recruitment
is ongoing with the goal of completing recruitment of 40,000 in-
dividuals, making this the largest single study of depression and an-
xiety. We hope that this paper will not only demonstrate the effec-
tiveness of the study methodology but will also raise awareness of the
availability of this cohort to researchers in the field and promote future
collaboration.
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Table 5
Current symptoms of psychopathology and impairment in the GLAD sample.
Mean Range SD Proportion Clinical Severity
Major depressive
disordera
11.00 0–27 6.92 Clinical (total) 83.7%
Mild (5–9) 24.7%
Moderate (10–14) 23.7%
Moderately severe
(15–19)
18.7%
Severe (20+) 16.7%
Generalised anxiety
disorderb
9.43 0–21 6.02 Clinical (total) 75.5%
Mild (5–9) 30.7%
Moderate (10–14) 21.1%
Severe (15+) 23.9%
Post-traumatic stress
disorderc
15.87 0–30 6.29 Clinical (14+) 60.2%
Personality disorderd 8.30 0–25 3.65 Clinical (total) 55.0%
Mild (8–9) 21.9%
Moderate (10+) 33.1%
Alcohol usee 7.06 0–40 6.48 At-risk (total) 38.7%
Increasing risk (8–15) 27.0%
Higher risk (16–19) 5.4%
Possible dependence
(20+)
6.4%
Functional Impairmentf 16.99 0–40 9.07 Clinical (total) 77.8%
Significant
impairment (10–20)
43.5%
Severe impairment
(21+)
34.4%
Percentages refer to the proportion of participants out of the total sample who
meet cut-off criteria on current measures for the specified disorder.
a Criteria met for major depressive disorder on PHQ-9 (Kroenke et al., 2001).
b Criteria met for generalised anxiety disorder on GAD-7 (Spitzer et al.,
2006).
c Criteria met for PTSD on PCL-6 (Lang et al., 2012) in the past month.
d Criteria met for a personality disorder on SASPD (Olajide et al., 2018).
e Criteria met for at-risk alcohol dependence on AUDIT (Saunders et al.,
1993) in the past year.
f Criteria met for functional impairment on WSAS (Mundt et al., 2002).
Fig. 7. Media campaign drivers to complete questionnaires, by age group.
Data is based on responses from 12,714 participants recruited in England be-
tween September–December 2019 to assess the success of the launch campaign.
Participants were prompted to select all relevant responses to the question
“How did you hear about the GLAD Study?” Social media refers to Facebook,
Twitter, Instagram, bloggers, and search engines. Traditional media refers to
radio, TV, newspaper, and online tabloids. All remaining responses are included
in the Other category.
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volunteers. GLAD is a project within the National Institute for Health
Research (NIHR) BioResource, and we thank the NIHR BioResource
staff for their assistance with the project. This study presents in-
dependent research funded by the NIHR Biomedical Research Centre at
South London and Maudsley NHS Foundation Trust and King's College
London. Further information can be found at http://brc.slam.nhs.uk/
about/core-facilities/bioresource. The views expressed are those of the
authors and not necessarily those of the NHS, NIHR, HSC R&D Division,
Department of Health, Queens University Belfast, or King's College
London.
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